ECO Animal Health Group (LON:EAH) Shares Pass Below 50 Day Moving Average - Should You Sell?

Key Points

• Shares crossed below its 50-day moving average (50 DMA GBX 106.17), trading as low as GBX 90 and last at GBX 95.11, roughly matching the 200-day MA of GBX 95.41—a sign of short-term weakness.
• Shore Capital raised its target from GBX 150 to GBX 160 and gave a "buy" rating; the stock's consensus rating is "Buy" with an average target of GBX 160.
• The company shows strong liquidity (current ratio 3.73, quick ratio 2.14) but a high debt-to-equity of 5.97, with a market cap of ~£63.8M and a P/E of ~21.7 indicating small-cap valuation metrics.

Shares of ECO Animal Health Group plc (LON:EAH - Get Free Report) crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of GBX 106.17 and traded as low as GBX 90. ECO Animal Health Group shares last traded at GBX 95.11, with a volume of 67,063 shares.

Analyst Ratings Changes

Separately, Shore Capital Group upped their target price on shares of ECO Animal Health Group from GBX 150 to GBX 160 and gave the company a "buy" rating in a research note on Tuesday, December 2nd. One analyst has rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of GBX 160.

ECO Animal Health Group Trading Down 0.4%

The firm has a 50-day moving average price of GBX 106.17 and a 200 day moving average price of GBX 95.41. The company has a current ratio of 3.73, a quick ratio of 2.14 and a debt-to-equity ratio of 5.97. The company has a market cap of £63.80 million, a price-to-earnings ratio of 21.67 and a beta of -0.05.

About ECO Animal Health Group

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline. Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide. Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.